Royal Jelly Research Articles

Chemical Characterization and Antioxidant Activity of Apilarnil, Royal Jelly, and Propolis Collected in Banat Region, Romania

Bee products have a millennia-old tradition in human apitherapy, thanks to their numerous curative properties. The aim of this study was to perform a physicochemical characterization, including the percentage of water content, dry matter, pH, acidity, impurity content, protein, ash, and macro and micro minerals, and to evaluate the antioxidant activity of apiculture products, including apilarnil, royal jelly, and propolis. Samples were collected from our apiary in the Banat region of Romania in 2022 as well as from the market. Apilarnil and royal jelly were analyzed in pure and freeze-dried form, and propolis in pure and tincture form. Our results show that there is a large variability in the chemical composition and antioxidant activity of the three bee products studied, depending on the form of presentation and source of origin. In the case of commercial bee products, the best results were obtained in terms of chemical composition, including the content of macro and micro nutrients. All the samples analyzed showed acidity, pH, and impurity content values within the limits allowed by the quality standards. Apilarnil from our own apiary recorded the highest values for antioxidant activity, followed by propolis tincture and fresh propolis from own apiary.

Research progress on rat model of drug-induced liver injury established by nonsteroidal anti-inflammatory drug (celecoxib) and royal jelly ameliorative effect.

NSAIDs, like celecoxib, are widely used to treat pain, fever, and inflammation, with celecoxib being particularly effective in managing arthritis symptoms and acute or chronic pain especially with its favorable gastrointestinal tolerability. The study aimed at exploring the effect of chronic administration of celecoxib on hepatic tissues in male albino rats. It also examined the royal jelly celecoxib interplay. 50 male albino rats in 5 equal groups; Group 1: received no drug. Group 2: received celecoxib (50 mg/kg/day, orally), for 30 successive days. Group 3: received celecoxib plus royal jelly (300 mg/kg/day, orally) for 30 successive days. Group 4: received celecoxib, for 30 days, then were left untreated for another 30 days. Group 5: received celecoxib plus royal jelly for 30 days, then were left untreated for another 30 days. Chronic celecoxib administration caused hepatotoxicity in male albino rats, with ameliorative effect of royal jelly. Celecoxib discontinuation significantly diminished the celecoxib-induced toxicity, and normal liver enzymes and serum protein levels were regained in the case of dual medications (celecoxib+RJ) discontinuation. Long-term celecoxib administration caused hepatotoxicity, with ameliorative effects of royal jelly against celecoxib-induced oxidative and apoptotic stress. In addition, it could be concluded that royal jelly may prove a useful adjunct in patients being prescribed celecoxib.

Exploring the Therapeutic Potential of Royal Jelly in Metabolic Disorders and Gastrointestinal Diseases.

Metabolic disorders, encompassing diabetes mellitus, cardiovascular diseases, gastrointestinal disorders, etc., pose a substantial global health threat, with rising morbidity and mortality rates. Addressing these disorders is crucial, as conventional drugs often come with high costs and adverse effects. This review explores the potential of royal jelly (RJ), a natural bee product rich in bioactive components, as an alternative strategy for managing metabolic diseases. RJ exhibits diverse therapeutic properties, including antimicrobial, estrogen-like, anti-inflammatory, hypotensive, anticancer, and antioxidant effects. This review's focus is on investigating how RJ and its components impact conditions like diabetes mellitus, cardiovascular disease, and gastrointestinal illnesses. Evidence suggests that RJ serves as a complementary treatment for various health issues, notably demonstrating cholesterol- and glucose-lowering effects in diabetic rats. Specific RJ-derived metabolites, such as 10-hydroxy-2-decenoic acid (10-HDA), also known as the "Queen bee acid," show promise in reducing insulin resistance and hyperglycemia. Recent research highlights RJ's role in modulating immune responses, enhancing anti-inflammatory cytokines, and suppressing key inflammatory mediators. Despite these promising findings, further research is needed to comprehensively understand the mechanisms underlying RJ's therapeutic effects.

Genetic parameters, trends, and inbreeding in a honeybee breeding program for royal jelly production and behavioral traits

An economically sustainable production of royal jelly (RJ) requires the use of genetics specifically improved for this very demanding trait. The French Royal Jelly Association has developed since 2010 a selection plan for that purpose, based on a collective data recording system and the initial seedstock of five French beekeepers. The aim of this study was to evaluate the efficiency of this collective breeding program, a decade after its concrete start. We considered three different genetic models to describe the phenotypes, hereafter named the Colony, Worker, and Queen Models. We showed that when the size and the structure of the dataset are insufficient to fit a Colony Model, fitting a Queen Model gives more understandable results for practical use of the estimated breeding values than the Worker Model. Regarding genetic parameters, we estimated moderate to high heritability values for all traits, regardless of the genetic model. Under a Queen Model, heritability estimates of RJ production were 0.19 ± 0.09 and 0.35 ± 0.13 for first and second harvests, respectively; the estimates were 0.76 ± 0.08, 0.29 ± 0.09, and 0.22 ± 0.08, respectively, for the calmness, gentleness, and spring development of the colony. We also proved that the breeding program is efficient, increasing the production at second harvest of 3.5% per year on average. Attention must, however, be paid to the evolution of inbreeding in this very small breeding population. Few genetic correlations were significantly different from zero between the traits, due to large standard errors of our estimates. It is, however, worth to note that the trends were generally favorable between all traits, which appears encouraging to improve production and behavioral traits jointly in the breeding program.

Effects of the royal jelly consumption on post-stroke complications in patients with ischemic stroke: results of a randomized controlled trial.

There is a paucity of evidence regarding the benefit of royal jelly (RJ) on post-stroke complications in patients with ischemic stroke. To address this knowledge gap, this randomized, triple-blind, placebo-controlled clinical trial was carried out to determine the effects of RJ consumption on post-stroke clinical outcomes. Of 64 eligible ischemic stroke patients (45-80 years), 32 were randomized to the RJ and 32 to the placebo groups and completed a 12-week intervention. The intervention group was advised to receive 1,000 mg of RJ dragee daily after breakfast. Post-stroke complications including cognition, fatigue, mental health, and appetite, along with serum levels of brain-derived neurotrophic factor (BDNF), and mid-upper arm circumference (MUAC) were assessed in groups pre-and post-intervention. After 12 weeks of RJ consumption, cognitive function [adjusted mean difference, 4.71; 95% confidence interval (CI), 1.75 to 7.67], serum levels of BDNF (adjusted mean difference, 0.36; 95% CI, 0.05 to 0.67), stress (adjusted mean difference, -3.33; 95% CI, -6.50 to -0.17), and appetite (adjusted mean difference, 1.38; 95% CI, 0.19 to 2.56) were significantly improved. However, the findings for fatigue (adjusted mean difference, -4.32; 95% CI, -10.28 to 1.63), depression (adjusted mean difference, -1.71; 95% CI, -5.58 to 2.16), anxiety (adjusted mean difference, -2.50; 95% CI, -5.50 to 0.49), and MUAC (adjusted mean difference, 0.36; 95% CI, -0.11 to 0.84) were less favorable. Findings support the benefits of RJ consumption in improving post-stroke complications and clinical outcomes.Clinical trial registration: https://www.irct.ir/trial/59275, Identifier IRCT20180818040827N4.

Simultaneous PCR detection of Paenibacillus larvae targeting insertion sequence IS256 and Melissococcus plutonius targeting pMP1 plasmid from hive specimens

Paenibacillus larvae and Melissococcus plutonius represent the most threatening bacterial diseases of honeybee (Apis mellifera)—American and European foulbrood, respectively. For efficient control of those diseases, rapid and accurate detection of the pathogens is crucial. Therefore, we developed a novel multiplex PCR method simultaneously detecting both pathogens. To design and optimize multiplex PCR reaction, four strains of P. larvae representing four ERIC genotypes I–IV (strain DSM 7030—ERIC I, DSM 25430—ERIC II, LMG 16252—ERIC III, DSM 3615—ERIC IV) were selected. Those strains were fully sequenced using long-read sequencing (Sequel I, Pacific Biosciences). For P. larvae, the multicopy insertion sequence IS256 identified in all genotypes of P. larvae was selected to provide high sensitivity. M. plutonius was detected by plasmid pMP1 sequence and the virulence verified by following detection of ETX/MTX2 toxin responsible for pore formation in the cell membrane. As an internal control, a gene encoding for major royal jelly protein 1 specific for honeybees was selected. The method was validated on 36 clinical specimens collected from the colonies suffering from American and European foulbrood in the Czech Republic. Based on the results, sensitivity of PCR was calculated to 93.75% and specificity to 100% for P. larvae diagnosed from hive debris and 100% sensitivity and specificity for honeybee workers and larval scales as well as for diseased brood infected by M. plutonius.

Jelleine, a Family of Peptides Isolated from the Royal Jelly of the Honey Bees (Apis mellifera), as a Promising Prototype for New Medicines: A Narrative Review.

The jelleine family is a group of four peptides (jelleines I-IV) originally isolated from the royal jelly of honey bee (Apis mellifera), but later detected in some honey samples. These oligopeptides are composed of 8-9 amino acid residues, positively charged (+2 to +3 at pH 7.2), including 38-50% of hydrophobic residues and a carboxamide C-terminus. Jelleines, generated by processing of the C-terminal region of major royal jelly proteins 1 (MRJP-1), play an important biological role in royal jelly conservation as well as in protecting bee larvae from potential pathogens. Therefore, these molecules present numerous benefits for human health, including therapeutic purposes as shown in preclinical studies. In this review, we aimed to evaluate the biological effects of jelleines in addition to characterising their toxicities and stabilities. Jelleines I-III have promising antimicrobial activity and low toxicity (LD50 > 1000 mg/Kg). However, jelleine-IV has not shown relevant biological potential. Jelleine-I, but not the other analogues, also has antiparasitic, healing, and pro-coagulant activities in addition to indirectly modulating tumor cell growth and controlling the inflammatory process. Although it is sensitive to hydrolysis by proteases, the addition of halogens increases the chemical stability of these molecules. Thus, these results suggest that jelleines, especially jelleine-I, are a potential target for the development of new, effective and safe therapeutic molecules for clinical use.

Long-term administration of royal jelly regulates age-related disorders and improves gut function in naturally aging mice.

A natural aging mouse model can exhibit physiological characteristics that closely resemble those of human aging. Through long-term observation, it reflects the occurrence and development of the aging process more accurately. Although numerous beneficial effects of royal jelly (RJ) have been extensively demonstrated in multiple experimental models, the effects of RJ on naturally aging mice have not yet been investigated. In this study, middle-aged male C57BL/6J mice were given RJ for 9 consecutive months to investigate its impact on the intestinal barrier function, gut microbiota, short-chain fatty acids (SCFAs) content and possible mechanisms. The results confirmed that RJ modulated serum lipids by reducing the levels of total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C). Additionally, it protected the liver by increasing antioxidant enzyme levels while decreasing inflammatory cytokines TNF-α (by 51.97%), IL-6 (by 29.73%), and IL-1β (by 43.89%). Furthermore, RJ inhibited the expression of cell cycle-dependent kinase inhibitors including p16, p21, and p53. Importantly, RJ ameliorated gut dysfunctions by inhibiting reduction of tight junction proteins and reducing inflammatory cytokines content in the colon. We also observed an alteration in gut microbiota characterized by an elevated ratio of Firmicutes to Bacteroides (F/B) along with increased abundance of beneficial bacteria, i.e., Lachnospiraceae NK4A136 and Akkermansia. Correlation analysis revealed positive associations between most bacterial genera and SCFAs production. Functional profiling of gut microbiota composition indicated that RJ intervention regulated amino acid metabolism, glycan biosynthesis, and cofactor/vitamin metabolism. Overall, our findings provide an effective dietary intervention strategy for modulating age-associated frailty through the modulation of the gut microbiota.

Quality indicators of compositions from drone brood and royal jelly

The purpose of the work was to compare two technological methods for preparing a combined product from royal jelly and drone brood. Methodology. The research was carried out at the Federal Scientific Center for Beekeeping. The material for the research was dry adsorbed drone brood, dried adsorbed royal jelly, compositions of royal jelly and drone brood prepared in two ways. The first method was the joint adsorption of royal jelly and drone brood, and the second was separate adsorption and drying followed by joint dry granulation of the components. The data obtained show that the differences in the physicochemical parameters of the products obtained by different methods are insignificant. The composition has intermediate values of physicochemical parameters between drone brood and royal jelly.

Comparison of the efficacy of royal jelly and melatonin combinations in experimentally induced wounds in geriatric and young mice.

Wound healing involves the repair of skin and other soft tissues after an injury. Royal jelly, a product of bees, possesses antioxidant, anti-inflammatory, antibacterial, and antiviral properties. Melatonin, a circadian indoleamine, is produced in the pineal gland and other organs. This study explores the effects of melatonin and royal jelly, both individually and combined, on wound healing in geriatric and young mice. The study includes 90 Balb/C mice divided into ten groups to assess the effects of royal jelly and melatonin on wound healing. Royal jelly was applied topically at a concentration of 300 mg/kg. Melatonin was formulated in a vaseline-based pomade at a concentration of 5 mg/kg. The substances were applied either separately or in combination to wounds created on the mice. Both substances significantly enhanced wound healing at a macroscopic level in both age groups. Melatonin was found to be more effective during the initial wound formation process, whereas royal jelly was more beneficial during the granulation phase. However, significant results at a histopathological level were observed only in geriatric animals. The findings suggest a potential new therapeutic approach to enhance wound healing, particularly in elderly individuals. However, these findings need to be supported through further research and clinical trials.

Royal jelly induces ROS-mediated apoptosis in acute lymphoblastic leukemia (ALL)-derived Nalm-6 cells: Shedding light on novel therapeutic approaches for ALL.

Until recently, a conventional chemotherapy regimen for Acute lymphoblastic leukemia (ALL) is considered an efficient therapeutic method in children. However, suboptimal long-term survival rates in adults, disease relapse, and drug-induced toxicities require novel therapeutic agents for ALL treatments. Today, natural products with pharmacological benefits play a significant role in treating different cancers. Among the most valued natural products, honey bees' royal jelly (RJ) is one of the most appreciated which has revealed anti-tumor activity against different human cancers. This study aimed to evaluate anti-leukemic properties and the molecular mechanisms of RJ cytotoxicity on ALL-derived Nalm-6 cells. The metabolic activity was measured by MTT assay. Apoptosis, cell distribution in the cell cycle, and intracellular reactive oxygen species (ROS) level were investigated using flow cytometry analysis. Moreover, quantitative real-time PCR (qRT-PCR) was performed to scrutinize the expression of various regulatory genes. RJ significantly decreased the viability of Nalm-6 cells but had no cytotoxic effect on normal cells. In addition, RJ induced ROS-mediated apoptosis by up-regulating pro-apoptotic genes while decreasing anti-apoptotic gene expression. The results outlined that ROS-dependent up-regulation of FOXO4 and Sirt1 inhibits the cells' transition to the S phase of the cell cycle through p21 up-regulation. The qRT-PCR analysis of autophagy-related gene expression also demonstrated that RJ induced BECN1 mediated autophagy in Naml-6 cells. Taken together, this study showed that RJ can be utilized as a potent natural substance to induce ALL cells' programmed cell death. However, further studies are required to examine this compound's pharmaceutical application.

Royal Jelly, A Super Food, Protects Against Celecoxib-Induced Renal Toxicity in Adult Male Albino Rats.

Celecoxib is a COX-2 nonsteroidal anti-inflammatory drug (NSAID). It is widely used for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. This study aimed to explore the effect of long-term administration of celecoxib on kidney of male albino rats, and to study the potential effect of treatment discontinuation on such tissues. The study also examined the alleged ameliorative effect of royal jelly (RJ). Fifty, male albino rats were divided into 5 equal groups; 10 each. Group 1: rats received no drug (control group). Group 2: rats received celecoxib (50 mg/kg/day, orally for 30 successive days). Group 3: rats received celecoxib (50 mg/kg/day, orally) and royal jelly (300 mg/kg/day, orally) for 30 successive days. Group 4: rats received celecoxib for 30 successive days, then rats were left untreated for another 30 days. Group 5: rats received celecoxib and RJ for 30 successive days, then rats were left untreated for another 30 days. Long-term celecoxib administration caused significant elevation in kidney function tests, with ameliorative effects of RJ against celecoxib-induced renal toxicity. Long-term celecoxib administration caused renal toxicity in male albino rats, with ameliorative effects of RJ.

Anti-oxidant and anti-apoptotic effects of royal jelly against polystyrene microplastic-induced testicular injury in mice.

In recent years, microplastics (MPs), which are novel environmental contaminants measuring 5 mm in diameter, have garnered considerable attention. However, information regarding substances that can mitigate the dangers of MPs for animals remains extremely limited. Ninety days were devoted to the exposure of mature male mice to royal jelly (RJ) and 2 µm virgin polystyrene microplastics (PS-MPs) in this study. Pre-implantation embryo development; the structure of testis tissue; the gonadosomatic index; sperm parameters; RNA damage in germinal cells; the anti-oxidant capacity of the entire testis; and the activity of anti-oxidant enzymes in serum and testicular tissue, including TAC, SOD dismutase, CAT, GSH, and MDA, histomorphometric indices of the testis (tubular differentiation index, spermatogenesis index, and repopulation index), steroidogenic foci, and the quantity of apoptosis were assessed in the testis, respectively, through the measurement of pro-apoptosis (p53, Bax, and Caspase-3) and anti-apoptosis (Bcl-2) factors, as well as Hsp70 mediator. The results indicate that concurrent administration of RJ can confer a protective effect on mice exposed to microplastics by maintaining the structure of mitochondria and enhancement of the anti-oxidant defense system. Furthermore, RJ co-treatment decreased apoptosis and oxidant/anti-oxidant status, enhanced pre-implantation embryo development, and improved sperm characteristics and RNA damage in germ cells. The data confirm that royal jelly could protect the testis structure against polystyrene microplastic-induced testicular injury through anti-oxidant and anti-apoptotic properties.

Effect of royal jelly on chronıc lıver and kıdney damage ınduced by cadmıum chlorıde ın rats

Forty eight rats were used to evaluate the protective effect of royal jelly (RJ) against chronic liver and kidney damage induced by cadmium chloride (CdCl2). In the histopathology of the CdCl2 group, the findings of inflammation and necrosis in liver sections, inflammation in kidney sections, proximal tubule degeneration and adiposity in the glomerulus were similar to the histopathological findings in the CdCl2 + RJ group. In immunohistochemical staining, it was determined that Caspase-3, Iba-1, KIM-1 and Tnf-a immunoreactivities in the liver and kidney tissue sections of the CdCl2-only group (Group III) were significantly increased compared to the control groups (Groups I, II). In the CdCl2 + RJ applied group (Group IV), Caspase-3, Iba-1, KIM-1 and TNF-α immunoreactivities were observed to be partially reduced compared to the CdCl2 (Group III) group. It was determined that AST, ALT, glucose, triglyceride, cholesterol and creatinine levels increased in the CdCl2 group and decreased in the CdCl2 + RJ group. While MDA levels increased in the group given only CdCl2 (Group III) compared to the control groups (Groups I, II), GSH levels decreased. In the CdCl2 + RJ group (Group IV), it was determined that MDA levels decreased and GSH levels increased compared to the CdCl2 (Group III) group. While the amounts of cadmium, zinc, copper, iron, magnesium and calcium in the liver tissue homogenates increased significantly in the CdCl2 group, it was observed that they decreased numerically in the CdCl2 + RJ group. This result shows that royal jelly application against CdCl2 toxicity does not prevent liver and kidney tissue damage, but can bring serum biochemical parameters, lipid peroxidation and trace element levels closer to control group levels.

Sebacic acid, a royal jelly-containing fatty acid, decreases LPS-induced IL-6 mRNA expression in differentiated human THP-1 macrophage-like cells.

Macrophages produce many inflammatory mediators, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), in innate immune responses. However, excess production of these mediators by activated macrophages triggers deleterious effects, leading to disorders associated with inflammation. Royal jelly (RJ), a milky-white substance secreted by worker bees, contains unique fatty acids, including 10-hydroxy-2-decenoic acid (10H2DA) and sebacic acid (SA). 10H2DA has been reported to have various biological functions, such as anti-inflammation. However, the anti-inflammatory effect of SA is not fully understood. In this study, we investigated the effects of SA on lipopolysaccharide (LPS)-induced cytokine expression using differentiated human THP-1 macrophage-like cells. SA dose-dependently decreased LPS-induced mRNA expression of IL-6, but not TNF-α and IL-1β. SA suppressed the phosphorylation of signal transducers and activators of transcription 1 (STAT1) and STAT3, but hardly affected the activation of JNK, p38, or NF-κB. In addition, SA decreased LPS-induced interferon-β (IFN-β) expression, and the addition of IFN-β restored the inhibition by SA of LPS-induced STAT activation and IL-6 expression. Furthermore, SA suppressed LPS-induced nuclear translocation of interferon regulatory factor 3 (IRF3), a transcription factor responsible for IFN-β expression. Taken together, we conclude that SA selectively decreases LPS-induced expression of IL-6 mRNA through inhibition of the IRF3/IFN-β/STAT axis.

Exploring the in vitro potential of royal jelly against glioblastoma and neuroblastoma: impact on cell proliferation, apoptosis, cell cycle, and the biomolecular content.

Neuroblastoma and glioblastoma are the most commonly seen nervous system tumors, and their treatment is challenging. Relatively safe and easy acquisition of nutraceutical natural products make them suitable candidates for anticancer research. Royal jelly (RJ), a superfood, has many biological and pharmacological activities. This study was conducted to, for the first time, elucidate its anticancer efficiency, even in high doses, on neuroblastoma and glioblastoma cell lines through cell viability, apoptosis, cell cycle and biomolecular content evaluation. We performed experiments with RJ concentrations in the range of 1.25-10 mg mL-1 for 48 h. Cell viability assays revealed a notable cytotoxic effect of RJ in a concentration-dependent manner. Treatment with a high dose of RJ significantly increased the apoptotic cell population of both cell lines. Furthermore, we observed G0-G1 phase arrest in neuroblastoma cells but G2-M arrest in glioblastoma cells. All these cellular changes are closely associated with the alterations of the macromolecular makeup of the cells, such as decreased saturated lipid, protein, DNA and RNA amounts, protein conformational changes, decreased protein phosphorylation and increased protein carbonylation. These cellular changes are associated with RJ triggered-ROS formation. The clear segregation between the control and the RJ-treated groups proved these changes, obtained from the unsupervised and supervised chemometric analysis. RJ has good anticancer activity against nervous system cancers and could be safely used with current treatment strategies.

Retracted: HS-GC-IMS and ATR-FT-MIR Analysis Reveal the Differences in Volatile Compounds, Proteins, and Polyphenols of Royal Jelly

Retracted: HS-GC-IMS and ATR-FT-MIR Analysis Reveal the Differences in Volatile Compounds, Proteins, and Polyphenols of Royal Jelly

Effect of digestion product of royal jelly protein on SGC-7901 gastric cancer cell

Royal jelly used for larvae and queens has many health-promoting properties such as spatial memory improvement, antibacterial activity and antioxidant capacity. However, the anticancer ability of the royal jelly is not unknown. In this study, effect of the royal jelly protein on SGC-7901 gastric cancer cell was investigated, and the key factors including the cell morphological, the colony formation, the proliferation, the cycle, and the expression of p53 and poly (ADP-ribose) polymerase-1 (PARP-1) proteins were analyzed. Result showed royal jelly protein was excellent in inhibiting the growth of SGC-7901gastric cancer cell. After treating with the digestion product of royal jelly protein (0.05 mg/mL～0.20 mg/mL), the morphological of gastric cancer cell significantly shrink, and both of density and quantity (1000～491) of gastric cancer cell significantly (p < 0.05) decreased. The proliferation of gastric cancer was strongest inhibited by 62.84 % of 0.20 mg/mL royal jelly protein. The expression of p53 and PARP-1 protein of gastric cancer cell was respectively enhanced (0.29～0.46) and reduced (0.51～0.42). Moreover, the higher content of royal jelly protein (0.05 mg/mL～ 0.2 mg/mL), the stronger inhibit ability of 45 SGC-7901 gastric cancer cell. In conclusion, royal jelly protein can be used as a potential food in adjunctive therapy for gastric cancer.

Honey: A Bioactive Resource for Diversified Therapeutic Use in Traditional Medicine

Abstract: Honey, a natural bioactive resource is obtained from Apis mellifera. It has been cherished as a natural product known for its dietary supplement and an effective remedy in traditional medicine to creation of nutraceuticals and functional foods in modern medicine of present generations. Apiculture is the practice of rearing honeybees, keeping them healthy and utilizing products like honey, bee pollen, bee bread and royal jelly for various purposes. The myriad benefits of natural products obtained from honeybees has been mentioned in the inscriptions and documents of several holy books like the Vedas, the Bible, and the Quran. and Bible. Bee products are known for their therapeutic use since ancient times in Egypt, Greece, and China. In India honeybee rearing is one of the traditional practices of indigenous community of ethnic tribes. It is a rich source of bioactive secondary metabolites like flavonoids, polyphenols, organic acids, vitamins, and minerals and thus contributes to its effectiveness in dietary supplement both as food and medicine. It also acts as an immunomodulator, anticancer, anti-inflammatory, antioxidant source and hence helps in curing various diseases. Due to its therapeutic characteristics, honey can be used to cure bronchial asthma, cough, TB, hepatitis, GI disorders and a variety of other ailments. Research investigations have proven that honey can also help in wound healing and in the treatment of ulcers. It is used in cosmetics to repair the skin by acting as an exfoliating agent and moisturizer in anti-tanning sunscreen lotions. The present research article highlights the comprehensive study on the efficacy of honey as a bio-resource for diversified therapeutic use in traditional medicine.

Antibacterial and Antifungal Activities of Apis mellifera L. Honey, Propolis, Royal Jelly in Iraqi Kurdistan Region

This study was conducted at a laboratory in the Biology, College of Education, University of Salahaddin, from February to May 2022 to investigate propolis, honey and royal jelly’s chemical composition, antioxidant and antibacterial activities. The honeybee production extract showed that Gram (+) bacteria were more resistant to the antibacterial compounds of honey and propolis than Gram (-) bacteria and fungi. E. coli was a more sensitive isolate than all the other bacteria examined against the honey types tested. At the same time, it revealed more resistance against all types of propolis. Royal jelly with honey displayed more antimicrobial activity than other bee products and exhibited superior activity; the minimum inhibitory concentration of honey and propolis samples ranged from 32 to 512µg/mL. The MIC value of the most effective honey (Honey 1, Honey 2 and Royal jelly) was 32µg/mL. The lowest concentration of Qaladze propolis was (32µg/mL) for E. coli ATCC 25922, followed by 128µg/mL in some other propolis types. Keywords: Apis mellifera; antimicrobial activities; honey; propolis; royal jelly.